{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:40:37Z","timestamp":1787010037193,"version":"build-2736575974"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6S","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,6]]},"abstract":"<jats:p>Invasive fungal diseases (IFD) are an important cause of morbidity and mortality in premature neonates and immunocompromised pediatric patients. Their diagnostic and therapeutic management remains a challenge. A nationwide survey was conducted among 13 of the largest pediatric units in the United Kingdom, to obtain insight in the current management of IFD in neonates and children. All responding centers were tertiary teaching centers. The use of fungal diagnostic tools and imaging modalities varied among centers. Antifungal prophylaxis was prescribed in most centers for extreme-low birth weight (LBW) infants and high-risk hemato-oncologic patients, but with a huge variety in antifungals given. An empirical treatment was favored by most centers in case of febrile neutropenia. First line therapy for candidemia consists of either fluconazole or liposomal amphotericin B, with voriconazole being first-line therapy for invasive aspergillosis. Disseminated invasive aspergillosis was most often mentioned as a reason to prescribe combination antifungal therapy. In conclusion, this survey reinforces the fact that there are still important aspects in the management of pediatric IFD which should ideally be addressed in pediatric clinical trials. Attention needs to be given the knowledge gaps as observed in the results of our survey to optimize the management of IFD in children and neonates.<\/jats:p>","DOI":"10.1097\/inf.0000000000002317","type":"journal-article","created":{"date-parts":[[2019,6,14]],"date-time":"2019-06-14T23:40:57Z","timestamp":1560555657000},"page":"S2-S6","source":"Crossref","is-referenced-by-count":41,"title":["Management of Invasive Fungal Disease in Neonates and Children"],"prefix":"10.1097","volume":"38","author":[{"given":"Laura","family":"Ferreras-Antol\u00edn","sequence":"first","affiliation":[{"name":"MRC Centre for Medical Mycology, Institute of Medical Sciences, University of Aberdeen, Aberdeen, United Kingdom"},{"name":"Paediatric Infectious Diseases Research Group, St. George\u2019s Hospital, St. George\u00b4s University London, University of London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike","family":"Sharland","sequence":"additional","affiliation":[{"name":"Paediatric Infectious Diseases Research Group, St. George\u2019s Hospital, St. George\u00b4s University London, University of London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adilia","family":"Warris","sequence":"additional","affiliation":[{"name":"MRC Centre for Medical Mycology, Institute of Medical Sciences, University of Aberdeen, Aberdeen, United Kingdom"},{"name":"Royal Aberdeen Children\u2019s Hospital, Aberdeen, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"issue":"suppl 1","key":"R1-20230912","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1093\/jpids\/pix046","article-title":"Epidemiology of invasive fungal disease in children.","volume":"6","author":"Pana","year":"2017","journal-title":"J Pediatric Infect Dis Soc"},{"key":"R2-20230912","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1586\/eri.11.1","article-title":"Invasive fungal infections in the pediatric population.","volume":"9","author":"Lehrnbecher","year":"2011","journal-title":"Expert Rev Anti Infect Ther"},{"key":"R3-20230912","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/j.1365-2141.2009.07844.x","article-title":"International variations in infection supportive care practices for paediatric patients with acute myeloid leukaemia.","volume":"147","author":"Lehrnbecher","year":"2009","journal-title":"Br J Haematol"},{"key":"R4-20230912","doi-asserted-by":"crossref","first-page":"e1019","DOI":"10.1542\/peds.2006-0446","article-title":"Antifungal prophylaxis to prevent neonatal candidiasis: a survey of perinatal physician practices.","volume":"118","author":"Burwell","year":"2006","journal-title":"Pediatrics"},{"key":"R5-20230912","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1128\/AAC.04109-14","article-title":"Systemic antifungal prescribing in neonates and children: outcomes from the Antibiotic Resistance and Prescribing in European Children (ARPEC) Study.","volume":"59","author":"Lestner","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"R6-20230912","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/ciw326","article-title":"Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America.","volume":"63","author":"Patterson","year":"2016","journal-title":"Clin Infect Dis"},{"key":"R7-20230912","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1093\/cid\/civ1194","article-title":"Executive summary: clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America.","volume":"62","author":"Pappas","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"suppl 7","key":"R8-20230912","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/1469-0691.12040","article-title":"ESCMID* guideline for the diagnosis and management of Candida diseases 2012: prevention and management of invasive infections in neonates and children caused by Candida spp.","volume":"18","author":"Hope","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"R9-20230912","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S1470-2045(14)70017-8","article-title":"Fourth European Conference on Infections in Leukaemia (ECIL-4): guidelines for diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or allogeneic haemopoietic stem-cell transplantation.","volume":"15","author":"Groll","year":"2014","journal-title":"Lancet Oncol"},{"key":"R10-20230912","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1093\/cid\/cir073","article-title":"Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america.","volume":"52","author":"Freifeld","year":"2011","journal-title":"Clin Infect Dis"},{"key":"R11-20230912","doi-asserted-by":"crossref","first-page":"e0140930","DOI":"10.1371\/journal.pone.0140930","article-title":"Meta-analysis and cost comparison of empirical versus pre-emptive antifungal strategies in hematologic malignancy patients with high-risk febrile neutropenia.","volume":"10","author":"Fung","year":"2015","journal-title":"PLoS One"},{"key":"R12-20230912","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1097\/INF.0000000000000101","article-title":"Role of management strategies in reducing mortality from invasive fungal disease in children with cancer or receiving hemopoietic stem cell transplant: a single center 30-year experience.","volume":"33","author":"Castagnola","year":"2014","journal-title":"Pediatr Infect Dis J"},{"key":"R13-20230912","doi-asserted-by":"crossref","first-page":"2860","DOI":"10.1093\/jac\/dky244","article-title":"Efficacy of pre-emptive versus empirical antifungal therapy in children with cancer and high-risk febrile neutropenia: a randomized clinical trial.","volume":"73","author":"Santolaya","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"R14-20230912","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1200\/JCO.2001.19.1.253","article-title":"Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia.","volume":"19","author":"Caillot","year":"2001","journal-title":"J Clin Oncol"},{"key":"R15-20230912","first-page":"1347","article-title":"Early detection of pneumonia in febrile neutropenic patients: use of thin-section CT.","volume":"169","author":"Heussel","year":"1997","journal-title":"Am J Radiol"},{"key":"R16-20230912","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1086\/588660","article-title":"Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer\/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC\/MSG) Consensus Group.","volume":"46","author":"De Pauw","year":"2008","journal-title":"Clin Infect Dis"},{"key":"R17-20230912","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.cmi.2018.01.002","article-title":"Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline.","volume":"24","author":"Ullmann","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"R18-20230912","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S1473-3099(15)70006-X","article-title":"British Society for Medical Mycology best practice recommendations for the diagnosis of serious fungal diseases.","volume":"15","author":"Schelenz","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"R19-20230912","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1093\/cid\/ciw592","article-title":"Galactomannan, \u03b2-D-glucan, and polymerase chain reaction-based assays for the diagnosis of invasive fungal disease in pediatric cancer and hematopoietic stem cell transplantation: a systematic review and meta-analysis.","volume":"63","author":"Lehrnbecher","year":"2016","journal-title":"Clin Infect Dis"},{"key":"R20-20230912","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s12281-017-0274-9","article-title":"Progress in the diagnosis of invasive fungal disease in children.","volume":"11","author":"Warris","year":"2017","journal-title":"Curr Fungal Infect Rep"},{"key":"R21-20230912","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1093\/jac\/dkr223","article-title":"Effect of azole antifungal therapy on vincristine toxicity in childhood acute lymphoblastic leukaemia.","volume":"66","author":"van Schie","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"R22-20230912","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/j.1439-0507.2011.02158.x","article-title":"Adverse interactions between antifungal azoles and vincristine: review and analysis of cases.","volume":"55","author":"Moriyama","year":"2012","journal-title":"Mycoses"},{"key":"R23-20230912","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1056\/NEJM199903113401004","article-title":"Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group.","volume":"340","author":"Walsh","year":"1999","journal-title":"N Engl J Med"},{"key":"R24-20230912","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1056\/NEJMoa040446","article-title":"Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia.","volume":"351","author":"Walsh","year":"2004","journal-title":"N Engl J Med"},{"key":"R25-20230912","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1097\/INF.0000000000000431","article-title":"Candida speciation, antifungal treatment and adverse events in pediatric invasive candidiasis: results from 441 infections in a prospective, multi-national study.","volume":"33","author":"Palazzi","year":"2014","journal-title":"Pediatr Infect Dis J"},{"key":"R26-20230912","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1111\/1469-0691.12578","article-title":"Neonatal invasive fungal infection in England 2004-2010.","volume":"20","author":"Oeser","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"R27-20230912","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.jinf.2012.08.003","article-title":"Clinical epidemiology of 960 patients with invasive aspergillosis from the PATH Alliance registry.","volume":"65","author":"Steinbach","year":"2012","journal-title":"J Infect"},{"key":"R28-20230912","doi-asserted-by":"crossref","first-page":"81","DOI":"10.7326\/M13-2508","article-title":"Combination antifungal therapy for invasive aspergillosis: a randomized trial.","volume":"162","author":"Marr","year":"2015","journal-title":"Ann Intern Med"},{"key":"R29-20230912","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1093\/jpids\/piu074","article-title":"A prospective, international cohort study of invasive mold infections in children.","volume":"4","author":"Wattier","year":"2015","journal-title":"J Pediatric Infect Dis Soc"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00006454-201906001-00002","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T18:18:35Z","timestamp":1694542715000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006454-201906001-00002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":29,"journal-issue":{"issue":"6S","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000002317","relation":{},"ISSN":["0891-3668"],"issn-type":[{"value":"0891-3668","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6]]}}}